Dementia with Lewy bodies (DLB): investigational treatments
Evidence-based neurology checklist on dementia with lewy bodies (dlb): investigational treatments: Disease modifying agents Elayta (CT1812) Fosgonimeton Ambroxol Anle138b Clenbuterol Tyrosine kinase inhibitors Neflamapimod Terazosin CT1812 Irsenontrine Zonisamide Symptomatic agents
Disease modifying agents
- Elayta (CT1812)
- Fosgonimeton
- Ambroxol
- Anle138b
- Clenbuterol
- Tyrosine kinase inhibitors
- Neflamapimod
- Terazosin
- CT1812
- Irsenontrine
- Zonisamide
Symptomatic agents
References
- Skylar-Scott IA, Sha SJ. Lewy Body dementia: an overview of promising therapeutics. Curr Neurol Neurosci Rep 2023 (Online ahead of print).
- MacDonald S, Shah AS, Tousi B. Current therapies and drug development pipeline in Lewy body dementia: an update. Drugs Aging 2022; 39:505-522.
- Chwiszczuk LJ, Breitve MH, Kirsebom BB, et al. The ANeED study - ambroxol in new and early dementia with Lewy bodies (DLB): protocol for a phase IIa multicentre, randomised, double-blinded and placebo-controlled trial. Front Aging Neurosci 2023; 15:1163184.
- Murata M, Odawara T, Hasegawa K, et al. Adjunct zonisamide to levodopa for DLB parkinsonism: a randomized double-blind phase 2 study. Neurology 2018; 90:e664-e672.
- Odawara T, Hasegawa K, Kajiwara R, et al. Long-term efficacy and safety of zonisamide for treatment of parkinsonism in patients with dementia with Lewy bodies: an open-label extension of a phase three randomized controlled trial. Am J Geriatr Psychiatry 2022; 30:314-328.
- And 2 more. Subscribe to see the full list
